Trials / Active Not Recruiting
Active Not RecruitingNCT04464200
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory B-cell Malignancies
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild side effects in participants. Once they find this dose, they can test it in future participants to see if it is effective in treating their relapsed/refractory B-cell cell cancers. This study will also look at whether 19(T2)28z1xx CAR T cells work against participants' cancer.
Conditions
- Diffuse Large B Cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Indolent Non-Hodgkin Lymphoma
- Marginal Zone Lymphoma
- Waldenstrom Macroglobulinemia
- Burkitt's Lymphoma
- Primary CNS Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 19(T2)28z1xx CAR T cells | 2-7 days following the completion of the conditioning chemotherapy, patients will receive the CAR- T cells by IV infusion over 1-3 days depending on the dose level and formulation of the final CAR- T cells. |
Timeline
- Start date
- 2020-07-06
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2020-07-09
- Last updated
- 2025-08-24
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04464200. Inclusion in this directory is not an endorsement.